Korea Investment CORP Invests $324.89 Million in AbbVie Inc. $ABBV

Key Points

• Korea Investment CORP acquired 1.29 million AbbVie shares worth approximately $324.9 million, making AbbVie its 25th-largest holding and representing about 0.6% of its portfolio.
• AbbVie exceeded quarterly expectations with EPS of $3.65 and revenue of $16.99 billion, while revenue rose 10.2% year over year. The company also issued third-quarter EPS guidance of $3.84–$3.88.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $275.95, although one firm lowered its 2026 EPS estimate. AbbVie’s $1.73 quarterly dividend provides a 2.7% yield.

Korea Investment CORP purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,291,102 shares of the company's stock, valued at approximately $324,893,000. AbbVie comprises approximately 0.6% of Korea Investment CORP's investment portfolio, making the stock its 25th largest holding. Korea Investment CORP owned about 0.07% of AbbVie as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Ranch Capital Advisors Inc. boosted its holdings in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock worth $3,238,000 after purchasing an additional 4,017 shares during the period. Capital Advisors Inc. OK raised its holdings in shares of AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock worth $112,516,000 after purchasing an additional 45,132 shares during the period. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of AbbVie during the second quarter worth $23,557,000. Wedge Capital Management L L P NC lifted its position in shares of AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock worth $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP lifted its position in shares of AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company's stock worth $17,376,000 after buying an additional 37,531 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and introduced HA 5 Hydra Collagen Facial Mist. Clinical testing reportedly showed a 30% reduction in skin dryness after two weeks, supporting AbbVie’s aesthetics and consumer-health growth strategy. SkinMedica Adds Barrier Calming Cream
• Positive Sentiment: AbbVie is cited as a potential beneficiary of an aging population, with its immunology portfolio positioned to capture long-term healthcare demand. Aging Population Drives Healthcare Growth
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. The event could provide updates on its pipeline, Humira replacement products and financial outlook, but no new information was announced yet. AbbVie Wells Fargo Healthcare Conference
• Neutral Sentiment: Investors are largely waiting for AbbVie’s next earnings update, leaving the stock without a major new near-term catalyst. AbbVie Stock Holds Steady
• Neutral Sentiment: New 340B-related court developments could affect drug-company pricing and reimbursement, but the article does not identify a specific immediate impact on AbbVie. 340B Court Updates
• Negative Sentiment: Erste Group Bank reduced its fiscal 2026 EPS estimate for AbbVie, signaling somewhat more cautious expectations for earnings growth. AbbVie FY2026 EPS Estimates Reduced

AbbVie Stock Performance

Shares of ABBV opened at $259.87 on Wednesday. The firm has a fifty day moving average of $253.69 and a 200-day moving average of $229.43. The company has a market cap of $459.14 billion, a price-to-earnings ratio of 73.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. Weiss Ratings raised shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. Evercore set a $235.00 target price on shares of AbbVie in a report on Friday, May 15th. BNP Paribas Exane lifted their target price on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Bank of America lifted their target price on AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Finally, Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $275.95.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source